Whereas ALK+ ALCL was recognized as a definite entity already in the 2008 WHO classification, systemic ALK− ALCL remained as a provisional entity, due to the lack of clear-cut criteria to distinguish it from other CD30-positive PTCLs [8]. Here, ALK is linked to anaplastic large cell lymphoma.